Get started
Author

Eric Burroughs Jordie

Observed name: Eric Jordie
ORCID: 0000-0002-7255-7495
Observed ORCID: 0000-0002-7255-7495
OpenAlex ID: A5023289286
Two heads are better than one: current landscape of integrating QSP and machine learning
2022 · Tongli Zhang, Ioannis P. Androulakis, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 65
PDF
A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti‐SARS‐CoV‐2 Monoclonal Antibodies to Advance Bamlanivimab Into a First‐in‐Human Clinical Trial
2021 · Emmanuel Chigutsa, Eric Jordie, et al. · Clinical Pharmacology & Therapeutics · 23
Bayesian PBPK modeling using R/Stan/Torsten and Julia/ SciML /Turing.Jl
2023 · Ahmed Elmokadem, Yi Zhang, et al. · CPT Pharmacometrics & Systems Pharmacology · 20
PDF
Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations
2021 · Ahmed Elmokadem, Christopher D. Bruno, et al. · The Journal of Clinical Pharmacology · 20
In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine
2023 · Paolo F. Caimi, Mehdi Hamadani, et al. · eJHaem · 13
PDF
Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment
2021 · Christopher D. Bruno, Ahmed Elmokadem, et al. · The Journal of Clinical Pharmacology · 13
CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling
2022 · Paolo F. Caimi, Mehdi Hamadani, et al. · Blood · 8
Landscape analysis for a neonatal disease progression model of bronchopulmonary dysplasia: Leveraging clinical trial experience and real-world data
2022 · Jeffrey S. Barrett, Megan Cala Pane, et al. · Frontiers in Pharmacology · 4
PDF
Understanding how CD19 expression levels impact the response to loncastuximab tesirine: a plain language summary
2024 · Paolo F. Caimi, Mehdi Hamadani, et al. · Future Oncology · 2
PDF
Development of an Agent‐Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec
2026 · Yuezhe Li, Partha Nandy, et al. · CPT Pharmacometrics & Systems Pharmacology · 1
Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy
2021 · Eric Burroughs Jordie, Leonid Gibiansky, et al. · British Journal of Clinical Pharmacology · 1
PDF
Development of an Agent-Based Model to Investigate Response Durability in Hemophilia B Patients Treated with the AAV-Based Coagulation Factor IX (FIX) Gene Therapy Etranacogene Dezaparvovec
2024 · Yuezhe Li, Partha Nandy, et al. · Blood
Works count: 12
Citation count: 170
H-index: 7
I10-index: 6
Year
Topic
Type